Is PHAR or ZLAB more profitable?

Pharming Group has a net margin of 2.51% compared to Zai Lab's net margin of -41.86%. Pharming Group's return on equity of 3.40% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets Pharming Group 2.51% 3.40% 1.90% Zai Lab -41.86% -27.43% -16.72%

Does the media favor PHAR or ZLAB?

In the previous week, Pharming Group had 4 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Pharming Group and 2 mentions for Zai Lab. Pharming Group's average media sentiment score of 0.60 beat Zai Lab's score of -0.14 indicating that Pharming Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, CDNA or PHAR?

Pharming Group has lower revenue, but higher earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CareDx $379.80M 7.40 -$21.35M $2.07 26.24 Pharming Group $376.13M 2.03 $2.85M $0.12 89.75

Is CDNA or PHAR more profitable?

CareDx has a net margin of 24.23% compared to Pharming Group's net margin of 2.51%. Pharming Group's return on equity of 3.40% beat CareDx's return on equity. Company Net Margins Return on Equity Return on Assets CareDx 24.23% 2.87% 2.17% Pharming Group 2.51% 3.40% 1.90%

Does the media prefer CDNA or PHAR?

In the previous week, CareDx and CareDx both had 6 articles in the media. CareDx's average media sentiment score of 0.80 beat Pharming Group's score of 0.60 indicating that CareDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CareDx 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PHAR or IMNM?

In the previous week, Pharming Group had 3 more articles in the media than Immunome. MarketBeat recorded 6 mentions for Pharming Group and 3 mentions for Immunome. Immunome's average media sentiment score of 0.77 beat Pharming Group's score of 0.60 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PHAR or NAMS?

In the previous week, NewAmsterdam Pharma had 4 more articles in the media than Pharming Group. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 6 mentions for Pharming Group. NewAmsterdam Pharma's average media sentiment score of 0.66 beat Pharming Group's score of 0.60 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NRIX or PHAR?

In the previous week, Pharming Group had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Pharming Group and 1 mentions for Nurix Therapeutics. Pharming Group's average media sentiment score of 0.60 beat Nurix Therapeutics' score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharming Group 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Pharming Group (PHAR) Competitors

$10.77 -0.49 (-4.35%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$10.75 -0.02 (-0.19%)

As of 04:35 AM Eastern

Compare

PHAR vs. ZLAB, CDNA, IMNM, NAMS, and NRIX

Should you buy Pharming Group stock or one of its competitors? Pharming Group's main competitors and comparable companies include Zai Lab (ZLAB), CareDx (CDNA), Immunome (IMNM), NewAmsterdam Pharma (NAMS), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pharming Group compare to Zai Lab?

Pharming Group (NASDAQ:PHAR) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Pharming Group has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Pharming Group has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.03	$2.85M	$0.12	89.75
Zai Lab	$460.16M	6.54	-$175.54M	-$1.71	N/A

Pharming Group presently has a consensus target price of $38.67, suggesting a potential upside of 259.02%. Zai Lab has a consensus target price of $37.25, suggesting a potential upside of 40.89%. Given Pharming Group's higher possible upside, research analysts plainly believe Pharming Group is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pharming Group has a net margin of 2.51% compared to Zai Lab's net margin of -41.86%. Pharming Group's return on equity of 3.40% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Zai Lab	-41.86%	-27.43%	-16.72%

In the previous week, Pharming Group had 4 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Pharming Group and 2 mentions for Zai Lab. Pharming Group's average media sentiment score of 0.60 beat Zai Lab's score of -0.14 indicating that Pharming Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pharming Group beats Zai Lab on 9 of the 17 factors compared between the two stocks.

How does Pharming Group compare to CareDx?

CareDx (NASDAQ:CDNA) and Pharming Group (NASDAQ:PHAR) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Pharming Group has lower revenue, but higher earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80M	7.40	-$21.35M	$2.07	26.24
Pharming Group	$376.13M	2.03	$2.85M	$0.12	89.75

CareDx has a net margin of 24.23% compared to Pharming Group's net margin of 2.51%. Pharming Group's return on equity of 3.40% beat CareDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	24.23%	2.87%	2.17%
Pharming Group	2.51%	3.40%	1.90%

In the previous week, CareDx and CareDx both had 6 articles in the media. CareDx's average media sentiment score of 0.80 beat Pharming Group's score of 0.60 indicating that CareDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

CareDx presently has a consensus price target of $51.20, suggesting a potential downside of 5.73%. Pharming Group has a consensus price target of $38.67, suggesting a potential upside of 259.02%. Given Pharming Group's higher probable upside, analysts clearly believe Pharming Group is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

0.0% of Pharming Group shares are owned by institutional investors. 2.4% of CareDx shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CareDx has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Summary

CareDx beats Pharming Group on 10 of the 15 factors compared between the two stocks.

How does Pharming Group compare to Immunome?

Pharming Group (NASDAQ:PHAR) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Pharming Group has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.03	$2.85M	$0.12	89.75
Immunome	N/A	N/A	-$212.39M	-$2.53	N/A

Pharming Group has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, Immunome has a beta of 2.13, indicating that its stock price is 113% more volatile than the broader market.

Pharming Group presently has a consensus target price of $38.67, indicating a potential upside of 259.02%. Immunome has a consensus target price of $35.18, indicating a potential upside of 45.14%. Given Pharming Group's higher probable upside, analysts plainly believe Pharming Group is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Pharming Group has a net margin of 2.51% compared to Immunome's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Immunome	N/A	-50.56%	-46.93%

In the previous week, Pharming Group had 3 more articles in the media than Immunome. MarketBeat recorded 6 mentions for Pharming Group and 3 mentions for Immunome. Immunome's average media sentiment score of 0.77 beat Pharming Group's score of 0.60 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Pharming Group beats Immunome on 9 of the 15 factors compared between the two stocks.

How does Pharming Group compare to NewAmsterdam Pharma?

Pharming Group (NASDAQ:PHAR) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Pharming Group has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.03	$2.85M	$0.12	89.75
NewAmsterdam Pharma	$22.50M	120.50	-$203.82M	-$2.16	N/A

Pharming Group has a net margin of 2.51% compared to NewAmsterdam Pharma's net margin of -3,644.21%. Pharming Group's return on equity of 3.40% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

In the previous week, NewAmsterdam Pharma had 4 more articles in the media than Pharming Group. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 6 mentions for Pharming Group. NewAmsterdam Pharma's average media sentiment score of 0.66 beat Pharming Group's score of 0.60 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharming Group has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

Pharming Group currently has a consensus price target of $38.67, indicating a potential upside of 259.02%. NewAmsterdam Pharma has a consensus price target of $49.73, indicating a potential upside of 119.26%. Given Pharming Group's higher possible upside, equities analysts clearly believe Pharming Group is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

NewAmsterdam Pharma beats Pharming Group on 9 of the 17 factors compared between the two stocks.

How does Pharming Group compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Pharming Group (NASDAQ:PHAR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Nurix Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

Pharming Group has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$36.77M	67.41	-$264.46M	-$3.45	N/A
Pharming Group	$376.13M	2.03	$2.85M	$0.12	89.75

0.0% of Pharming Group shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Pharming Group had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Pharming Group and 1 mentions for Nurix Therapeutics. Pharming Group's average media sentiment score of 0.60 beat Nurix Therapeutics' score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharming Group	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharming Group has a net margin of 2.51% compared to Nurix Therapeutics' net margin of -928.44%. Pharming Group's return on equity of 3.40% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Pharming Group	2.51%	3.40%	1.90%

Nurix Therapeutics currently has a consensus target price of $34.21, suggesting a potential upside of 43.28%. Pharming Group has a consensus target price of $38.67, suggesting a potential upside of 259.02%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Pharming Group beats Nurix Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Pharming Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAR vs. The Competition

Export

Metric	Pharming Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$796.96M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	89.75	13.88	274.07	25.69
Price / Sales	2.03	1,356.95	643.13	79.17
Price / Cash	56.14	113.29	77.80	52.76
Price / Book	2.73	15.40	10.47	6.32
Net Income	$2.85M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-0.09%	-1.71%	-0.67%	0.17%
1 Month Performance	-6.02%	-6.18%	-3.17%	-3.27%
1 Year Performance	-27.38%	30.64%	15.13%	5.58%

Pharming Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAR Pharming Group	4.3498 of 5 stars	$10.77 -4.4%	$38.67 +259.0%	-27.1%	$796.96M	$376.13M	89.75	407	Analyst Forecast
ZLAB Zai Lab	2.2263 of 5 stars	$24.87 +1.2%	$37.25 +49.8%	-17.6%	$2.84B	$460.16M	N/A	1,784	News Coverage
CDNA CareDx	2.7725 of 5 stars	$53.37 +1.9%	$51.20 -4.1%	+248.8%	$2.77B	$379.80M	25.87	765
IMNM Immunome	2.9322 of 5 stars	$23.95 -2.5%	$34.64 +44.6%	+129.5%	$2.73B	N/A	N/A	177	Analyst Forecast
NAMS NewAmsterdam Pharma	3.5543 of 5 stars	$21.40 -4.3%	$49.73 +132.4%	-15.0%	$2.56B	$7.12M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAR) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharming Group (PHAR) Competitors

PHAR vs. ZLAB, CDNA, IMNM, NAMS, and NRIX

How does Pharming Group compare to Zai Lab?

Summary

How does Pharming Group compare to CareDx?

Summary

How does Pharming Group compare to Immunome?

Summary

How does Pharming Group compare to NewAmsterdam Pharma?

Summary

How does Pharming Group compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharming Group (PHAR) Competitors

PHAR vs. ZLAB, CDNA, IMNM, NAMS, and NRIX

How does Pharming Group compare to Zai Lab?

Which has more volatility and risk, PHAR or ZLAB?

Which has preferable valuation and earnings, PHAR or ZLAB?

Do analysts rate PHAR or ZLAB?

Do institutionals & insiders hold more shares of PHAR or ZLAB?

Is PHAR or ZLAB more profitable?

Does the media favor PHAR or ZLAB?

Summary

How does Pharming Group compare to CareDx?

Which has higher valuation and earnings, CDNA or PHAR?

Is CDNA or PHAR more profitable?

Does the media prefer CDNA or PHAR?

Do analysts prefer CDNA or PHAR?

Do institutionals & insiders have more ownership in CDNA or PHAR?

Which has more risk & volatility, CDNA or PHAR?

Summary

How does Pharming Group compare to Immunome?

Which has better valuation & earnings, PHAR or IMNM?

Which has more risk & volatility, PHAR or IMNM?

Do analysts recommend PHAR or IMNM?

Is PHAR or IMNM more profitable?

Does the media favor PHAR or IMNM?

Do institutionals and insiders believe in PHAR or IMNM?

Summary

How does Pharming Group compare to NewAmsterdam Pharma?

Which has higher earnings and valuation, PHAR or NAMS?

Is PHAR or NAMS more profitable?

Does the media favor PHAR or NAMS?

Which has more volatility & risk, PHAR or NAMS?

Do analysts recommend PHAR or NAMS?

Do insiders and institutionals believe in PHAR or NAMS?

Summary

How does Pharming Group compare to Nurix Therapeutics?

Which has more volatility and risk, NRIX or PHAR?

Which has better earnings and valuation, NRIX or PHAR?

Do insiders & institutionals hold more shares of NRIX or PHAR?

Does the media prefer NRIX or PHAR?

Is NRIX or PHAR more profitable?

Do analysts recommend NRIX or PHAR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools